DNA repair dysregulation from cancer driver to therapeutic target.
about
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinomaMaintaining Genome Stability in Defiance of Mitotic DNA DamageTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyThe detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinomaThe clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerThe RNA Splicing Response to DNA DamageHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerInhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapyDNA damage response and prostate cancer: defects, regulation and therapeutic implicationsBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsMicrobiota impact on the epigenetic regulation of colorectal cancerLow ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicClinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancerUpdate on immune checkpoint inhibitors in gynecological cancersCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordDNA ligase IV syndrome; a reviewUbiquitylation, neddylation and the DNA damage responseSystematic E2 screening reveals a UBE2D-RNF138-CtIP axis promoting DNA repairPARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersPersonalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.DNA damage response genes and the development of cancer metastasisFission yeast Rad52 phosphorylation restrains error prone recombination pathwaysMonitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid ModelRecommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast CancerInvolvement of DNA damage response pathways in hepatocellular carcinoma.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.Circadian Clock, Cell Division, and Cancer: From Molecules to Organism.Exploring functions of long noncoding RNAs across multiple cancers through co-expression networkPituitary gland development and disease: from stem cell to hormone productionPoly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.Drugging the Cancers Addicted to DNA Repair.Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival.
P2860
Q21558626-042DA377-4BE0-4966-B8CF-07278B2794D2Q26738970-DB0F8797-45E1-43CC-85F6-0F2D5D8DD4F4Q26745686-7CBD2FD2-FA3E-4606-89E7-6E1CBED4247AQ26750641-A64E8F97-4914-48ED-8409-295ABBB8D82DQ26766285-1B8F2D4A-016B-4190-8199-EB90D07158B6Q26776513-6D24D0EB-5DFE-4048-8EED-AFEC674908C6Q26777046-F7A9D718-B5AC-49F9-B7B8-B345A7A1C16AQ26783551-CE1EF861-0697-4278-AF62-FAB721D57D2AQ26796576-76D5180E-ACB5-4804-9DBC-C124867FB106Q26829155-2F705F27-4532-432D-9E2F-BB5F7C14CD38Q26852274-8C40BCAC-A235-4D56-A55E-9639D3621CB1Q27028132-CBB33302-8DBE-4D64-BCB9-4EB19408044DQ27853007-B4A89023-B468-44CE-B6AB-BE8963D7E942Q28071345-768E6AB9-6B64-4184-9F45-15208B41A3EFQ28071541-74F7EF1B-061B-465D-8819-5ABE5D0CACC8Q28072263-12C37CDB-66DA-4E11-A7E9-55BD9C88820CQ28076497-69EE63B2-005A-4728-9949-4B4927E3AB59Q28078268-866D0E2E-DA6F-4455-8518-035330E12AEBQ28080075-5735EB6F-94AA-46AE-B216-D56CE19945A3Q28087342-99FB9870-FCCA-4758-B2DD-3BF629A82608Q28115456-C50B16C4-E8C7-4F27-AF43-FD75A8C6A3BAQ28254261-5656FDCF-FE82-4B21-BCB3-871D09D1F25DQ28271944-80624650-8364-4937-8BD0-B5AFE09DD9F5Q28294205-EA297F24-C7E2-4AC1-9F14-6EF4D2C37981Q28388312-C6B87601-4B28-43DC-BDE1-AA89E9934A81Q28538056-0FD3E3DF-7DD2-4C67-B316-3E86AEEBB7FEQ28546906-1ED87451-B7B7-40A8-B16B-AF03CA8B6C62Q30250038-7B5EB6B5-729C-4D97-B974-9B0E0A7215C6Q30966966-9EE20481-5F82-4690-9B82-E32553A56CBAQ31132980-3B7C6536-6BC8-45E8-8B2D-610AB42B7B09Q33616812-BF4D6FF9-0E64-4CD6-8EFB-9826BCFC72BCQ33617922-76AEEBFD-3610-4AE9-9AD1-379CE2CE4F15Q33618432-50D1C520-60BD-414E-BD86-A4F6829BCB62Q33624949-002F78C5-1356-4EAC-B36F-0349DBCB2A20Q33677918-045C894C-6FBF-425B-A42B-9C121F113945Q33687947-EE1E78FA-2CE4-4EE8-89F0-ABC55023AEADQ33688658-B97D42CF-C896-4DC9-95C1-8AC6260A49B4Q33698648-E5562C89-3ABB-4074-BDC1-39440B8AC634Q33702497-A5B39398-1F33-41CC-883A-4DFA3B002077Q33705389-1F6741F3-CB7F-41B6-88E0-4FBD47BAC477
P2860
DNA repair dysregulation from cancer driver to therapeutic target.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
DNA repair dysregulation from cancer driver to therapeutic target.
@en
type
label
DNA repair dysregulation from cancer driver to therapeutic target.
@en
prefLabel
DNA repair dysregulation from cancer driver to therapeutic target.
@en
P356
P1476
DNA repair dysregulation from cancer driver to therapeutic target.
@en
P2093
Nicola J Curtin
P2888
P304
P356
10.1038/NRC3399
P407
P577
2012-12-01T00:00:00Z
P6179
1015345471